ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OPTI.GB Optibiotix Health Plc

18.50
0.00 (0.00%)
06:55:41 - Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc AQSE:OPTI.GB Aquis Stock Exchange Ordinary Share GB00BP0RTP38
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 18.50 17.50 19.50 18.50 18.50 18.50 0.00 06:55:41
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

OptiBiotix Health PLC Increased investment in THWLC (1138T)

03/01/2017 7:00am

UK Regulatory


Optibiotix Health (AQSE:OPTI.GB)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Optibiotix Health Charts.

TIDMOPTI

RNS Number : 1138T

OptiBiotix Health PLC

03 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Increased investment in The Healthy Weight Loss Company Ltd

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces an increase in its investment in its majority owned subsidiary The Health Weight Loss Company Limited ("THWLC").

Under the terms of the agreement OptiBiotix has made an investment of GBP75,000 to provide working capital to support marketing and an increase in stock levels. This investment increases OptiBiotix's shareholding in THWLC to 64%.

OptiBiotix announced on 26 July 2016 that it had acquired a majority shareholding in THWLC to incubate new technological solutions and develop wider product applications in weight management. THWLC produces GoFigure(R) products containing SlimBiome(R) which incorporates OptiBiotix's patented combination of natural ingredients developed by experts to support weight loss (see www.GoFigureDiet.com). Since investment:-

-- THWLC has gained over 1,000 customers, retail listings in over 80 stores, and 4 distributorships in the UK and Iceland

-- Sales have outperformed expectations with GoFigure(R) products receiving excellent customer reviews on Amazon and customer surveys reporting average weight loss of 2 1/2 lbs per week

-- GoFigure(R) was voted finalist in "Best New Health & Nutrition" at the 2016 European Natural & Organic Awards

-- As announced on 13 December 2016 GoFigure(R) products have attracted corporate interest leading to an agreement with a major multinational to develop food and Over The Counter ("OTC") products containing OptiBiotix's SlimBiome(R) technology for the Asian market,

This increased investment will provide THWLC with the resources to build on its early success to:-

   1.    Invest in product marketing at key seasonal periods 
   2.    Provide the marketing support required for listing in major retail outlets 

3. Increase the number of retail listings, particularly with major retail outlets, selling GoFigure(R) products both within the UK and internationally

Stephen O'Hara, CEO of OptiBiotix, commented: "We are really pleased with the progress of THWLC and the rapid sales growth of its GoFigure(R) products which have shown the unique ability of our SlimBiome(R) technology to help customers lose weight without feeling hungry, leading to easier and more successful dieting. Our belief in the potential of THWLC is demonstrated by this additional investment which provides funds to invest in marketing, to build stock levels to meet the seasonal demand for weight management products, and to support an increase in retail listings, particularly with major retail outlets. I am sure investors will recognise that given the early success of GoFigure(R) products, which has been achieved without any marketing, there is potential for strong sales growth of GoFigure(R) products over the next few years and substantial value enhancement."

For further information, please contact:

 
 OptiBiotix Health plc                             www.optibiotix.com 
 Stephen O'Hara, Chief Executive                          Contact via 
                                                       Walbrook below 
 
 Cairn Financial Advisers LLP                           Tel: 020 7213 
                                                                 0883 
 Liam Murray 
 
   finnCap Broker                                       Tel: 020 7220 
                                                                 0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
  Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                            Tel: 020 7933 8780 or 
                                           optibiotix@walbrookpr.com 
 Anna Dunphy                                           Mob: 07876 741 
                                                                  001 
 Mike Wort                                             Mob: 07900 608 
                                                                  002 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About The Healthy Weight Loss Company

The Healthy Weight Loss Company (THWLC) is jointly owned by OptiBiotix Health plc (64%), Anna Maia, and Max Tomlinson. The Company was formed in July 2016 as a platform for OptiBiotix to incubate new technological solutions and develop wider product applications in weight management.

The technology incubator was created to provide an effective way to substantiate the commercial viability of early product concepts. THWLC sells GoFigure(R) snacks and shakes containing OptiBiotix's proprietary Slimbiome(R) technology under a non-exclusive UK license agreement. www.GoFigureDiet.com. The use of SlimBiome(R) in the GoFigure(R) range establishes use of the technology in food products and supports the wider use of Slimbiome(R) technology in dietary supplements and over the counter (OTC) applications, both in the UK and internationally.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBRBDDBBXBGLG

(END) Dow Jones Newswires

January 03, 2017 02:00 ET (07:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart

Your Recent History

Delayed Upgrade Clock